Owlstone Medical (Cambridge, UK), the worldwide chief in Breath Biopsy® for functions in early illness detection and precision drugs, immediately introduced that it has entered right into a Analysis Settlement with Bicycle Therapeutics plc (NASDAQ: BCYC, “Bicycle”), a biotechnology firm pioneering a brand new and differentiated class of therapeutics based mostly on its proprietary bicyclic peptide (Bicycle®) know-how.
Underneath the Settlement, the Corporations will examine the potential of mixing applied sciences and strategies to develop antigen-targeted diagnostic probes that use bicyclic peptides as their focusing on mechanism linked with Owlstone’s Exogenous Unstable Natural Compound (EVOC®) Probes. Work will initially give attention to lung most cancers screening as the primary proof of precept for the broader alternative by selling selective accumulation of the probe on the tumor for elevated sign and enhanced specificity.
If profitable, the ensuing antigen-targeted EVOC Probes may have the potential to be used in pre-clinical analysis to assist each cell-based and in-vivo research; in scientific trials for affected person stratification and measurement of goal engagement; and as companion diagnostics to establish responders/non-responders for remedy choice and to measure goal engagement over the course of remedy.
Owlstone is creating diagnostic assessments in areas of excessive unmet scientific want together with for the early detection of lung most cancers, the most typical most cancers on the planet. To assist this effort, Owlstone has pioneered the usage of EVOC Probes in early detection and precision drugs, with the Firm’s lead EVOC Probe in scientific trials. This probe makes use of the exercise of enzymes expressed throughout the tumor microenvironment to launch a risky reporter chemical that may be detected on breath when a tumor is current. The mixed method to be explored beneath the Settlement will exploit Bicycle’s proprietary Bicycle know-how to direct binding and accumulation of the probe on tumor cells, following which elevated ranges of the reporter chemical can be launched.
Billy Boyle, co-founder and CEO at Owlstone Medical, mentioned: “We’re dedicated at Owlstone to remodeling diagnostics by the sooner detection of illness by breath, and are all the time looking for revolutionary approaches to additional improve the efficiency of our assessments. By our partnership with Bicycle, we are going to collectively discover the thrilling prospects of a mixed antigen-targeted EVOC method for a broad vary of precision drugs functions, initially for the early detection of lung most cancers to assist Owlstone’s ongoing work on this space.”
About Owlstone Medical:
Owlstone Medical’s imaginative and prescient is to save lots of 100,000 lives by realizing the large promise of breath-based diagnostics by the event and utility of Breath Biopsy®, a singular platform able to each biomarker discovery and use in routine scientific testing.
The platform contains ReCIVA®, a proprietary pattern assortment gadget that may take steady breath samples anyplace, the world’s solely industrial Breath Biopsy Laboratory positioned in Cambridge, U.Okay., and the Breath Biopsy VOC Atlas, probably the most intensive catalogue of recognized risky natural compounds (VOCs) generally discovered on breath. The Firm’s know-how is protected by over 120 granted and pending patents and has been utilized in greater than 100 analysis papers.
Owlstone Medical’s Analysis Merchandise and Companies are being deployed at over 100 websites world wide with giant pharmaceutical corporations together with AstraZeneca, Actelion (a J&J firm), and GlaxoSmithKline, and main educational establishments. Initiatives are supported by Breath Biopsy OMNI®, probably the most superior resolution for dependable end-to-end international breath VOC evaluation, which helps researchers advance biomarker discovery and illness analysis and maximizing the probabilities of discovering clinically related breath biomarkers.
The corporate has an energetic portfolio of Breath Biopsy assessments in improvement for the early detection of lung most cancers and liver illness, each areas of excessive unmet scientific want that characterize multi-billion greenback market alternatives. In digestive well being, scientific assessments for Small Intestinal Bacterial Overgrowth and carbohydrate malabsorption are already on market, and breath testing is rising as an efficient approach for sufferers to observe and handle signs.
The submit Owlstone Medical enters partnership with Bicycle Therapeutics for the event of antigen-targeted EVOC probes for early most cancers detection appeared first on BioTechniques.